BKA
PRAX icon

Brick & Kyle Associates’s Praxis Precision Medicines PRAX Stock Holding History

Brick & Kyle Associates’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$311K Hold
966
– – 0.1% 79
2026
Q1 		$311K Buy
+966
New +$299K 0.1% 79

Other funds holding PRAX

JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Brick & Kyle Associates's PRAX Position: Q2 2026 in Review

Brick & Kyle Associates held its Praxis Precision Medicines (PRAX) position steady in Q2 2026 at 966 shares worth $311K. The position accounts for 0.1% of the portfolio, ranked #79.

Brick & Kyle Associates first reported a position in PRAX in Q1 2026 and has held it in 2 quarters since. 310 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

  • Brick & Kyle Associates held 966 shares of Praxis Precision Medicines worth $311K as of Q2 2026.
  • Brick & Kyle Associates left its Praxis Precision Medicines share count unchanged in Q2 2026.
  • Praxis Precision Medicines made up 0.1% of Brick & Kyle Associates's portfolio in Q2 2026, its #79 holding.
  • Brick & Kyle Associates first reported a position in Praxis Precision Medicines in Q1 2026 and has held it in 2 quarters since.
  • 310 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Brick & Kyle Associates's 13F filing for Q2 2026, filed 6 Aug 2026.